MedTrace Logo

Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

NCT01792713 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-05-20

No results posted yet for this study

Summary

Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis

Conditions

  • Skin Alterations Associated With Atopic Dermatitis

Interventions

DRUG

Sertaconazole 2% cream

DRUG

Placebo

Sponsors & Collaborators

  • Spirig Pharma Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-09-30
Completion
2014-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01792713 on ClinicalTrials.gov